24th Nov 2015 07:00
Ap27
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader | J.P. Morgan Securities LLC. |
Company dealt in | Pfizer Inc |
Class of relevant security to which the dealings being disclosed relate (Note 1) | Common Stock |
Date of dealing | 20 November 2015 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)
Class of relevant security: | Long | Short | ||||
Common Stock | Number | (%) | Number | (%) | ||
(1) Relevant securities | 5,251,990 0.09 | 4,108,861 0.07 | ||||
(2) Derivatives (other than options) | 1,239,408 0.02 | 2,496,887 0.04 | ||||
(3) Options and agreements to purchase/sell | 9.437.270 0.15 | 6,709,300 0.11 | ||||
Total | 14,555,643 0.26 | 13,315,048 0.22
| ||||
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)
Class of relevant security: | Long | Short | ||||
Number | (%) | Number | (%) | |||
(1) Relevant securities | ||||||
(2) Derivatives (other than options) | ||||||
(3) Options and agreements to purchase/sell | ||||||
Total | ||||||
Ap28
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchases/ sales
| Number of relevant securities | Price per unit (USD) |
Purchases
Sales | 1,000,000 400 400 1,900 200 600 5,100 3,500 2,400 1,600 1,300 1,952 2,900 2,900 800 1,700 1,428 4,900 136,003 3,200 272 1,100 2,100 3,300 2,800 100 300 200 1,200 500 3,200 17,331 400 2,700 6,550 5,558 1,300 36,778 9,423 12,148 500 13,200 3,242 9,215 10,004 4,805 19,944 14,600 15,500 27,100 10,200 304,800 3,500 56 2,338 828 1,100 1,834 500 400 2,800 17,600 200
500,000 101,372 6,295 3,300 3,497 16,996 4,779 53,170 3,067 4,618 2,800 6,391 1,800 175,413 1,040 1,650 9,500 600 1,182 2,800 800 800 200 45,332 7,775 45,461 120,900 1,000 6,900 800 1,700 9,150 1,200 4,564 11,500 45,914 700 1,300 2,266 289 3,849 100 2,100 5,900 100 4,316 800 190,000 4,730 4,200 9,244 18,394 7,332 4,000 70,944 | 32.0000 32.1150 32.1200 32.1247 32.1300 32.1400 32.1450 32.1464 32.1500 32.1525 32.1550 32.1596 32.1600 32.1638 32.1650 32.1700 32.1738 32.1750 32.1800 32.1850 32.1868 32.1900 32.1925 32.1950 32.2000 32.2025 32.2050 32.2100 32.2650 32.2680 32.2700 32.2796 32.2800 32.2850 32.2871 32.2879 32.2885 32.2900 32.2926 32.2937 32.2940 32.2944 32.2946 32.2950 32.2953 32.2962 32.2963 32.2971 32.2973 32.3000 32.3034 32.3200 32.4050 32.4500 32.4664 32.4715 32.4732 32.4751 32.4760 32.4775 32.4800 32.5477 32.5500
32.0000 32.1800 32.2800 32.2850 32.2863 32.2892 32.2898 32.2900 32.2946 32.2947 32.2950 32.2977 32.2994 32.3000 32.3023 32.3032 32.3050 32.3100 32.3115 32.3150 32.3162 32.3175 32.3200 32.3631 32.3900 32.3954 32.3956 32.3960 32.3986 32.3988 32.4000 32.4030 32.4033 32.4048 32.4050 32.4104 32.4150 32.4200 32.4218 32.4250 32.4290 32.4300 32.4375 32.4600 32.4650 32.4800 32.4838 32.4842 32.4850 32.4883 32.4892 32.4923 32.4950 32.5400 32.5500 |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 5) | Number of relevant securities (Note 6) | Price per unit (USD) (Note 4) |
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 4) |
Call Option Call Option Call Option Call Option Call Option Call Option Call Option Call Option Call Option Put Option Put Option Put Option Put Option Put Option Put Option Put Option Put Option Put Option Put Option
| Purchasing Purchasing Selling Selling Selling Selling Selling Selling Selling Purchasing Purchasing Selling Selling Selling Selling Selling Selling Selling Selling | 130,000 2,000,000 500,000 250,000 600,000 50,000 130,000 14,700 15,100 2,000,000 745,000 4,200 500,000 508,100 91,900 500,000 14,500 21,100 600,000 | 34.50 32.50 32.50 32.50 32.50 33.00 33.00 34.00 33.00 32.00 30.00 32.00 32.00 32.00 32.00 31.00 31.00 32.00 32.00 | American American American American American American American American American American American American American American American American American American American | 11/12/15 27/11/15 27/11/15 27/11/15 27/11/15 11/12/15 11/12/15 18/03/15 18/03/15 27/11/15 19/02/15 27/11/15 27/11/15 27/11/15 27/11/15 19/02/15 18/03/16 18/03/16 18/03/16 | 0.15 0.44 0.45 0.46 0.47 0.62 0.68 1.19 1.61 0.25 0.92 0.23 0.25 0.32 0.33 1.23 1.49 1.90 2.07 |
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (USD) (Note 4) |
Call Option Call Option Put Option | 500,000 1,000,000 1,000,000 | 32.00 32.00 33.50 |
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Nature of transaction (Note 7) | Details | Price per unit (if applicable) (Note 4) |
Ap29
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities
under any option referred to on this form or relating to the voting rights or future acquisition
or disposal of any relevant securities to which any derivative referred to on this form is referenced.
If none, this should be stated.
Is a Supplemental Form 38.5(b) attached? (Note 8) YES
Date of disclosure | 23 November 2015 |
Contact name | Tung Le |
Telephone number | 020 7742 7272 |
Name of offeree/offeror with which connected | Allergan plc |
Nature of connection (Note 9) | Adviser to Allergan plc |
SUPPLEMENTAL FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
(This form should be attached to Form 38.5(b)) OPEN POSITIONS (Note 1)
Product name, e.g. call option | Written or purchased | Number of relevant securities to which the option or derivative relates | Exercise price (Note 2)(USD) | Type, e.g. American, European etc. | Expiry date |
Call option
| Purchased | 30,000 | 35.00 | American | 20/01/17 |
Call option | Purchased | 70,000 | 37.00 | American | 20/01/17 |
Call option | Purchased | 363,900 | 35.00 | American | 15/01/16 |
Call option | Purchased | 700 | 38.00 | American | 15/01/16 |
Call option | Written
| 2,500 | 28.00 | American | 15/01/16 |
Call option | Written | 14,700 | 30.00 | American | 15/01/16 |
Call option | Written | 200 | 37.00 | American | 15/01/16 |
Call option | Written | 150,000 | 37.00 | American | 15/01/16 |
Call option | Written | 50,000 | 33.00 | American | 18/12/15 |
Call option | Written | 6,000 | 34.00 | American | 18/12/15 |
Call option | Written | 7,600 | 32.00 | American | 15/01/16 |
Call option | Purchased | 383,200 | 34.71 | European | 21/12/15 |
Call option | Purchased | 383,200 | 34.71 | European | 21/12/15 |
Call option | Purchased | 127,794 | 35.28 | European | 03/12/15 |
Call option | Purchased | 120,533 | 35.66 | European | 12/01/16 |
Call option | Purchased | 48,943 | 36.47 | European | 25/01/16 |
Call option | Written | 200,000 | 33.00 | European | 16/12/16 |
Call option | Written | 383,200 | 34.71 | European | 21/12/15 |
Put option | Purchased
| 30,000 | 35.00 | American | 20/01/17 |
Put option | Purchased | 20,000 | 35.00 | American | 20/01/17 |
Put option | Purchased | 4,300 | 30.00 | American | 15/01/16 |
Put option | Purchased | 2,800 | 28.00 | American | 15/01/16 |
Put option | Purchased | 300 | 32.00 | American | 15/01/16 |
Put option | Purchased | 150,000 | 30.00 | American | 16/09/16 |
Put option | Purchased | 100,000 | 36.00 | American | 18/03/16 |
Put option | Purchased | 32,900 | 32.00 | American | 15/01/16 |
Put option | Written | 9,200 | 33.00 | American | 19/02/16 |
Put option | Written | 19,100 | 31.00 | American | 19/02/16 |
Put option | Written | 5,300 | 23.00 | American | 15/01/16 |
Put option | Written | 100,000 | 30.00 | American | 15/01/16 |
Put option | Written | 5,600 | 25.00 | American | 15/01/16 |
Put option | Written | 250,000 | 28.00 | American | 15/01/16 |
Put Option | Written | 500,000 | 33.00 | American | 18/03/16 |
Put Option | Purchased | 200,000 | 33.00 | European | 16/12/16 |
Put Option | Written
| 117,900 | 35.00 | American | 17/06/16 |
Put Option | Written | 62,400 | 35.00 | American | 17/06/16 |
Put Option | Written | 71,300 | 35.00 | American | 17/06/16 |
Put Option | Written | 646,800 | 35.00 | American | 17/06/16 |
Put Option | Written | 154,500 | 35.00 | American | 17/06/16 |
Put Option | Written | 308,100 | 35.00 | American | 17/06/16 |
Put Option | Written
| 139,000 | 35.00 | American | 17/06/16 |
Put Option | Written
| 450,000 | 35.00 | American | 15/01/16 |
Callable Barrier Reverse Convertible Note | Purchased | 183,430 | 32.71 | N/A | 21/03/17 |
Callable Barrier Reverse Convertible Note | Purchased | 30,572 | 32.71 | N/A | 21/03/17 |
Auto-callable Barrier Reverse Convertible Note | Purchased | 45,984 | 32.62 | N/A | 17/03/17 |
Barrier Reverse Convertible Note | Purchased | 30,408 | 34.53 | N/A | 05/04/16 |
Equity Linked Note | Purchased | 6,740 | 29.67 | N/A | 03/02/16 |
Leveraged Accumulator | Purchased | 14,874 + | 29.12 | N/A | 12/09/16 |
Callable Barrier Reverse Convertible Note | Written | 183,430 | 32.71 | N/A | 21/03/17 |
Callable Barrier Reverse Convertible Note | Written | 30,572 | 32.71 | N/A | 21/03/17 |
Auto-Callable Barrier Reverse Convertible Note | Written | 45,984 | 32.62 | N/A | 17/03/17 |
Barrier Reverse Convertible Note | Written | 30,408 | 34.53 | N/A | 05/04/16 |
Equity Linked Note | Written | 6,740 | 29.67 | N/A | 03/02/16 |
Leveraged Accumulator | Written | 14,874 + | 29.12 | N/A | 12/09/16 |
Leveraged Accumulator | Written | 9,000+ | 31.70 | N/A | 04/03/16 |
Auto-callable Optimization Securities | Written | 7,851 | 27.60 | N/A | 25/06/20 |
Equity Linked Note | Written | 6,740 | 29.67 | N/A | 03/02/16 |
Callable Barrier Reverse Convertible Note | Written | 183,430 | 32.71 | N/A | 21/03/17 |
Callable Barrier Reverse Convertible Note | Written | 30,572 | 32.71 | N/A | 21/03/17 |
Auto-Callable Barrier Reverse Convertible Note | Written | 45,984 | 32.62 | N/A | 17/03/17 |
Barrier Reverse Convertible Note | Written | 30,408 | 34.53 | N/A | 05/04/16 |
Leveraged Accumulator | Written | 14,874 + | 29.12 | N/A | 12/09/16 |
Put Option | Purchased | 457,000 | 27.50 | N/A | 11/01/16 |
Callable Barrier Reverse Convertible | Purchased | 22,929 | 32.71 | N/A | 21/03/17 |
Auto-Callable Barrier Reverse Convertible Note | Purchased | 7,685 | 32.53 | N/A | 15/03/17 |
Auto-Callable Barrier Reverse Convertible Note | Purchased | 11,189 | 32.62 | N/A | 17/03/17 |
Barrier Reverse Convertible Note | Purchased | 178 | 2.44 | N/A | 05/04/16 |
Equity Link Note | Purchased | 31,133 | 32.12 | N/A | 15/12/15 |
Equity Link Note | Written | 31,133 | 32.12 | N/A | 15/12/15 |
Equity Link Note | Written | 31,133 | 32.12 | N/A | 15/12/15 |
Put Option | Purchased | 50,000 | 33.00 | American | 18/12/15 |
Call Option | Purchased | 200,000 | 34.00 | American | 04/12/15 |
Call Option | Purchased | 500,000 | 32.00 | American | 18/03/16 |
Call Option | Written | 1,000,000 | 32.00 | American | 18/03/16 |
+ This instrument is physically settled, and the interest in shares has been calculated as the maximum number of Pfizer shares that the counterparty could be obliged to buy at the exercise price
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rules 8 and
38.5 of the Rules. If in doubt, consult the Panel.
Related Shares:
PFZ.L